Showing results (1211-1220 of 1,427) with videos related to

Sort By:
Pageof 143
Pediatrics|June 19, 2013
"Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreakErin F Mathes, Vikash Oza, Ilona J Frieden, et al.
Genome Medicine|November 2, 2018
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivorsS Y Cindy Yang, Stephanie Lheureux, Katherine Karakasis, et al.
Gynecologic Oncology|February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 studyFabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.
Heart Rhythm|March 7, 2026
The Impact of Vein of Marshall Alcohol or Radiofrequency Ablation in Patients with Persistent Atrial Fibrillation Undergoing Catheter Ablation in the REAL-AF RegistryNicholas Palmeri, Sarah Neilsen, Jordan Leyton-Mange, et al.
Translational Oncology|August 24, 2025
Elucidating divergent biology in uterine carcinosarcomaVikas Garg, Stephenie D Prokopec, Simone C Stone, et al.
The Lancet. Oncology|August 7, 2021
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trialBradley J Monk, Nicoletta Colombo, Amit M Oza, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Risk in the "Red Zone": Outcomes for Children Admitted to Ebola Holding Units in Sierra Leone Without Ebola Virus DiseaseF Fitzgerald, K Wing, A Naveed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2017
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid TumorsRebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
Pageof 143